Synergistically Enhanced in-Vitro Cytotoxicity and Overall Survival in NSG Xenografts Against Burkitt Lymphoma (BL) and Primary Mediastinal Large B Cell Lymphoma (PMBL) by Polatuzumab Vedotin (hu- anti-CD79b-vc-MMAE, PV) Alone or In-Combination With Obinutuzumab

Document Type

Abstract

Publication Date

9-2018

DOI

10.1111/bjh.15536

Journal Title

British Journal of Haematology

Department

Pediatrics

Second Department

Health Behavior and Community Health

This document is currently not available here.

Share

COinS